In loving memory of

Paul Ichiro Terasaki

1929–2016

Paul Terasaki holding a laboratory plate

Contribution to research

Dr. Tambur is honored and grateful to be supported by generous grants supported by Mark Terasaki in memory of his late father

Below is a list of publications from our laboratory that were funded by the grants

Visit the Paul I. Terasaki Research Fund
Paul Terasaki in the laboratory

Supported publications

Portrait of Paul Terasaki
  1. Lockhart J.S., Lantz C.W., & Tambur A.R. (2025). Blind Spots in HLA Class II Detection Generate Challenges for Antibody and RNA-based Assays.Transplantation. 2025 Dec;():10.1097/TP.0000000000005592.
  2. Lefaucheur C., Louis K., Morris A.B., Taupin J-L., Nickerson P., Tambur A.R., Gebel H.M., Reed E.F.; STAR 2022 Working Group (2023). Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document. Am J Transplant. 2023 Jan;23(1):115-132.
  3. Meneghini M., & Tambur A.R. (2023). HLA-DQ antibodies in alloimmunity, what makes them different? Curr Opin Organ Transplant. 2023 Oct;28(5):333-339.
  4. Meneghini M., & Tambur A.R. (2024). HLA (emphasis on DQ) compatibility for longer allograft survival in pediatric transplantation: Modern evidence and challenges. Pediatr Transplant. 2024 Feb;28(1):e14606.
  5. Tambur A.R., Audry B., Glotz D., & Jacquelinet C. (2023). Improving equity in kidney transplant allocation policies through a novel genetic metric: The Matched Donor Potential. Am J Transplant. 2023 Jan;23(1):45-54.
  6. Tambur A.R., & Das R. (2023). Can We Use Eplets (or Molecular) Mismatch Load Analysis to Improve Organ Allocation? The Hope and the Hype. Transplantation. 2023 Mar;107(3):605-615. 
  7. Tambur A.R., & Schinstock C. (2022). Clinical utility of serial serum dilutions for HLA antibody interpretation. HLA 2022 Nov;100(5):457-468.
  8. Isaacson D., Schold J.D., Gmeiner M.W., Copley H.C., Kosmoliaptsis V., & Tambur A.R.(2022). HLA-DQ Mismatches Lead to More Unacceptable Antigens, Greater Sensitization, and Increased Disparities in Repeat Transplant Candidates. J Am Soc Nephrol. 2022 Dec;33(12):2293-2305.
  9. Saleem N., Das R., & Tambur, A.R. (2022). Molecular Histocompatibility Beyond Tears: The next generation version.Hum Immunol. 2022 Mar;83(3):233-240.
  10. Tambur A.R., Schinstock C.A., Maguire C.H., Lowe D., Smith B., & Stegall M. (2021). Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. Am J Transplant. 2021 Mar;21(3):1278-1284. 
  11. Tambur A.R., Kosmoliaptsis V., Claas F.H.J., Mannon R.B., Nickerson P., & Naesens M. (2021). Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney Int. 2021 Nov;100(5):1012-1022.
  12. Engen R.M., Jedraszko A.M., Conciatori M.A., & Tambur A.R. (2020) Substituting imputation of HLA antigens for high resolution HLA typing: Evaluation of a multiethnic population and implications for molecular mismatch evaluation for clinical decision making. Am J Transplant. 2021 Jan;21(1):344-352.
  13. García-Sánchez C., Usenko C.Y., Herrera N.D., & Tambur A.R. (2020). The shared epitope phenomenon – a potential impediment to virtual crossmatch accuracy. Clinical Transplantation 2020;34(8):e13906.  
  14. Tambur A.R., Campbell P., Chong A.S., Feng S., Ford M.L., Gebel H., Gill R.G., Kelsoe G., Kosmoliaptsis V., Mannon R.B., Mengel M., Reed E.F., Valenzuela N.M., Wiebe C., Dijke I.E., Sullivan H.C., & Nickerson P. (2020). Sensitization in Transplantation: Assessment of Risk (STAR) 2019 Working Group Meeting Report. Am J Transplant 2020; 20(10):2652-2668.
  15. Tambur A.R., McDowell H., Hod-Dvorai R., Abundis M.A.C., & Pinelli D.F. (2019). The quest to decipher HLA immunogenicity: Telling friend from foe. Am J Transplant 2019 Jun;19(5):2910-2925.
  16. Tambur A.R. (2018) HLA-epitope matching or eplet risk stratification: The devil is in the details. Front Immunol. 2018 Aug;9:2010.
  17. Pinelli D.F., Zachary A.A., Friedewald J.J., Gjertson D.W., Evans M.A., Chatroop E.N., Leffell M.S., Vo A.A., Jordan S.C., Montgomery R.A.,  & Tambur A.R. (2019). Prognostic tools to assess candidacy for an efficacy of antibody-removal therapy. Am J Transplant 2019 Feb;19(2):381-390.
  18. Tambur A.R., Campbell P., Claas F.H., Feng S., Gebel H.M., Jackson A.M., Mannon R.B., Reed E.F., Tinckam K., Askar M., Chandraker A., Chang P.P., Colvin M., Demetris A.J., Diamond J.M., Dipchand A.I., Fairchild R.L., Ford M.L., Friedewald J., Gill R.G., Glotz D., Goldberg H., Hachem R., Knechtle S., Kobashigawa J., Levine D.J., Levitsky J., Mengel M., Milford E., Newell K.A., O'Leary J.G., Palmer S., Randhawa P., Smith J., Snyder L., Starling R.C., Sweet S., Taner T., Taylor C.J., Woodle S., Zeevi A., & Nickerson P. (2018) Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplant 2018 Jul;18(7):1604-1614.
  19. Cusick M.F., & Tambur A.R. (2015). Advancing Histocompatibility Testing for Solid Organ Transplantation – What is Needed? A Personal Opinion. Clin Transpl. 2015:31:193-201.